How to change the price of imported medicines due to rising exchange rates and whether Russian developments that can replace foreign drugs , understood the science department "Gazety.Ru" .
Where are imported medicines
To understand what will happen to the prices of medicines in the conditions when the dollar rises , it is necessary to present the way in which drugs are brought to market . We buy tablets and capsules in the pharmacy , and the pharmacy shelf , they fall through the distribution companies that buy drugs from manufacturers. In the role of producers increasingly advocated by international pharmaceutical companies have their representatives in Russia , sometimes Russian manufacturers producing generic drugs - drugs reproduced under the generic name , and very rarely - innovative drugs .
Although generic contain the same active ingredient as the original drug , and they are tested for therapeutic equivalence of efficacy in most cases lower than those of the original drugs.
Thus, the main market participants : producers, distributors and pharmacies. Procurement for themselves there are two ways . Every year the Ministry of Health carries out through distributors government procurement of certain drugs in the first place on the list of vital and essential drugs ( VED ) . While the purchase prices are determined through tenders . But the company's distributors work with producers and myself, and this part of the purchase price , of course, no one regulates. And in different pharmacies prices for the same drug can vary considerably , as pharmacies, as any company engaged in the retail sale, set the trading margin . And there is a national network of pharmacies as a fixed mark-up , and much more numerous private pharmacy chains .
The dollar and the euro are rising and prices of medicines ?
With the increase in the dollar would naturally expect higher prices for imported drugs , and experts confirm this.
They expect growth in retail prices by 15% as a minimum.
But since there are pharmaceutical warehouses supply of drugs , the rise in prices will occur gradually over a period of 3-4 months .
Changes do not have to touch the drugs listed VED as they are fixed margins . In 2014, this list contains the same number as in 2012 (567 names of drugs).
However , experts say it may be an additional problem for the manufacturer . Since the margin is not revised , if the producers will find it unprofitable supply of drugs , they can stop them .
" The devaluation of the ruble led to higher prices for drugs that are not included in the VED - said " Gazeta.ru " experts of the Russian branch of the international pharmaceutical company " Novartis " . - However, it will strike for more patients to pay for drugs . "
Russian pharmaceutical market changes began to occur and to increase the exchange rate . As told "Gazeta.ru" Orestes Ibragimov , CEO of the Russian pharmaceutical company OOO " Izvarino Pharma ", " last year has shown that the Russian pharmaceutical market ( in the absolute number of packages of drugs ) observed a slight tendency to reduce , change in exchange rates will accelerate this process .
People will be more selective about what to buy or not to buy the drug , especially if it is an expensive drug , and often decide not to buy, due to the fact that they can not afford. "
At the same time, the volume of public procurement and purchase prices for them, according to experts, should not change this year , despite fluctuations in the exchange rate, since the trades have already passed , the agreement signed with pharmaceutical companies , the prices are fixed. And next year is likely to change the budget for public procurement .
It also reaffirmed " the Newspaper " and experts "Novartis" :
Within the framework of public procurement prices probably will not rise due sfederalnym law of contractual procurement system ( FL -44 ), which is likely to lead to fixing auction prices in rubles at the level of last year. "
In the current environment is natural to expect that the Russian market will turn to the Russian manufacturer . Although a ban on the purchase of imported drugs , like prohibition of purchases of imported medical equipment, which is contained in a bill introduced by the Ministry of Industry is obviously impossible , the share of domestic pharmaceutical market can change. Although experts do not expect a significant increase it .
"This trend is very weak, - said " Gazeta.ru " Orestes Ibragimov . - Judging by the pharmaceutical market analyst reports , changing this ratio is very slightly. Though in the case of expensive drugs procured by the state , the changes are more visible to a greater extent due to the program Minpromtorga Strategy pharmaceutical development until 2020. The program really works , now have domestic substitutes drugs that effectively replace imports , and the government has already acquired such drugs . It is generic , or, more correctly , generics . "
As the experts say , " Novartis ", " Major trends in public procurement of drugs - dzhenerikozameschenie . While domestic generics receive a 15 percent price preference in tenders . "
As for the original , innovative domestic pharmaceutical products , their share in the total volume of pharmaceutical development and, accordingly , the market share so far is negligible . Experts estimate it is no more than 1 %.
This before , "Gazeta.ru" said Dr. Alexander Chemistry Gabibov expert scientific and technical council Minpromtorga "Now Russian innovation is sufficiently small. The Russian market is moving towards the creation of generic drugs . And maybe this is the right path of growth of the pharmaceutical industry , because we need to create a database . "
Although attempts to increase the share of domestic pharmaceutical development undertaken . " The program is supporting the development of local drugs also realized Minpromtorgom - says Orest Ibragimov . - A number of companies carries out its development in this direction , such as the company " KhimRar " is a Russian manufacturer, has a lot of development of innovative drugs . Our company " Izvarino Pharma" is also moving in this direction , we develop innovative medicines in collaboration with "Rusnano" .
Enumerating the Russian innovations , Alexander Gabibov mentioned antibacterial and antiviral drugs that are created in the Institute. Gamal , neurotropic drugs that are created in the Institute of Pharmacology RAMS , and the development of drugs based on recombinant proteins. Add a drug for the treatment of HIV infection , created at the Research Institute of Chemical Diversity " KhimRar ", which is undergoing clinical trials .
Yet, experts do not expect that the share of Russian innovative products on the market will grow substantially . As stressed by Orest Ibragimov, "because the pharmaceutical market differs from other certain conservatism .
And also because it makes no sense for pharmaceutical companies to implement innovative developments in one country . We can only talk about pharmaceutical developments with interest for the global market .
These are the realities of globalization. Companies who undertake innovations , globalization should have ambitions of these developments on the world market . Such companies in the Russian units . "
Source : www.recipe.ru